Screening patients for asymptomatic microhematuria does not appear to improve outcomes, since screening does not identify a population with increased prevalence of urologic malignancy (strength of recommendation [SOR]: A, based on prospective cohort studies) or the presence of urologic disease of any type (SOR: B, based on 1 cohort study). Asymptomatic microhematuria is sometimes associated with urologic disease that requires intervention to prevent death or disability (SOR: B, based on cohort studies). However, no studies demonstrate improved outcomes from screening for asymptomatic microhematuria
